相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Methotrexate mechanism in treatment of rheumatoid arthritis
Benjamin Friedman et al.
JOINT BONE SPINE (2019)
Janus kinases to jakinibs: from basic insights to clinical practice
Massimo Gadina et al.
RHEUMATOLOGY (2019)
STAT signaling as a marker of SLE disease severity and implications for clinical therapy
Ales Goropevsek et al.
AUTOIMMUNITY REVIEWS (2019)
Selective Janus kinase inhibitors come of age
John J. O'Shea et al.
NATURE REVIEWS RHEUMATOLOGY (2019)
Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials
Simon Tarp et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
Gerd R. Burmester et al.
LANCET (2018)
Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review
Paul Emery et al.
ADVANCES IN THERAPY (2018)
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)
R. Westhovens et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Low-dose methotrexate in myeloproliferative neoplasm models
Kavitha Chinnaiya et al.
HAEMATOLOGICA (2017)
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
Roy Fleischmann et al.
LANCET (2017)
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Daniella M. Schwartz et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
The emerging safety profile of JAK inhibitors in rheumatic disease
Kevin L. Winthrop
NATURE REVIEWS RHEUMATOLOGY (2017)
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials
Simon Tarp et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2017)
Low-dose methotrexate in myeloproliferative neoplasm models
Kavitha Chinnaiya et al.
HAEMATOLOGICA (2017)
Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
Roy Fleischmann et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis
Jackie L. Nam et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Low-dose methotrexate as treatment of myeloproliferative neoplasms: Proof of principle of clinical activity
Francesca Palandri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial
Johannes W. J. Bijlsma et al.
LANCET (2016)
Methotrexate affects HMGB1 expression in rheumatoid arthritis, and the downregulation of HMGB1 prevents rheumatoid arthritis progression
Yuan-bo Li et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2016)
Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures
Joel M. Kremer et al.
RMD OPEN (2016)
Incidence of herpes zoster in Japanese patients with rheumatoid arthritis from 2005 to 2010
Ayako Nakajima et al.
MODERN RHEUMATOLOGY (2015)
Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs
Dimitrios A. Pappas et al.
ARTHRITIS CARE & RESEARCH (2015)
Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
Paul Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Methotrexate Is a JAK/STAT Pathway Inhibitor
Sally Thomas et al.
PLOS ONE (2015)
Methotrexate-mediated inhibition of nuclear factor κB activation by distinct pathways in T cells and fibroblast-like synoviocytes
Charles F. Spurlock et al.
RHEUMATOLOGY (2015)
Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
James D. Clark et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
Glynn Dennis et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis
Martin E. Dowty et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Adenosine augments IL-10-induced STAT3 signaling in M2c macrophages
Balazs Koscso et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
Identification and Characterization of the Direct Interaction between Methotrexate (MTX) and High-Mobility Group Box 1 (HMGB1) Protein
Yuki Kuroiwa et al.
PLOS ONE (2013)
Regulation of inflammation by adenosine
Gyoergy Hasko et al.
FRONTIERS IN IMMUNOLOGY (2013)
Regulation of Macrophage Function by Adenosine
Gyorgy Hasko et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald F. van Vollenhoven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Novel Protein Kinase Signaling Systems Regulating Lifespan Identified by Small Molecule Library Screening Using Drosophila
Stephen R. Spindler et al.
PLOS ONE (2012)
Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis model
Misato Hashizume et al.
ARTHRITIS RESEARCH & THERAPY (2012)
Janus kinases in immune cell signaling
Kamran Ghoreschi et al.
IMMUNOLOGICAL REVIEWS (2009)
Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3
Nam-Hoon Kim et al.
IMMUNOLOGY (2007)
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
FC Breedveld et al.
ARTHRITIS AND RHEUMATISM (2006)
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
JCW Edwards et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years
GF Ferraccioli et al.
RHEUMATOLOGY (2002)
Methotrexate suppresses NF-κB activation through inhibition of IκBα phosphorylation and degradation
S Majumdar et al.
JOURNAL OF IMMUNOLOGY (2001)
分享论文
